This summary was created by AI, based on 20 opinions in the last 12 months.
Thermo Fisher Scientific is a global leader in scientific devices and tools for the bio-pharma industry. Despite challenges post-Covid, the company is expected to see revenue growth reaccelerate. The long-term prospects for this stock are positive, with steady earnings growth and a strong position in the healthcare industry. While there has been some inventory destocking and weaker demand, analysts generally view this stock favorably for long-term investors.
Scores 10/10 in her book. A global leader in scientific devices. Earnings grew double digits in the past 5 years and she expects steady growth to come. They raised EPS guidance from $21.35 to $22.00. There's 17% upside.
(Analysts’ price target is $658.50)Still owns business. Excellent business. Expecting earnings to grow. Ability to grow in USA very good. Slow and steady growth - defensive name. Very good for a long term investor.
All the tools and services that the healthcare industry needs, so you get diversity with just the one stock. Very well managed. Long-term growth targets are 7-9%. Always improves margins. China is about 8% of revenues, a bit weaker. Biotech funding dried up with higher rates. Inventory destocking. Hopefully, those 3 factors are behind them.
Likes it. Great job improving ROE, pretty stable sales growth. Estimate for 2025 is 11-12% earnings growth. Technically, sets up well.
Benefitted from Covid, but afterwards there was too much inventory. But the PE fell from 30x to 20x, and is exiting the excess and entering a long cycle. Will grow earning 10-15% including by acquisition. Healthcare/pharma/biotech he expects will grow.
It made a buy list today and deserved it. They're starting to see a rebound after Covid. They have a lot of diagnostic equipment that's widely used across healthcare. Shares are earnings are coming out of the doldrums and starting to move up.
World leader, dominates the industry. Not cheap, but solid long-term grower.
Still very positive, especially as spending by pharmaceuticals is getting more robust.
They delivered today a strong earnings and revenue beat as they raised their full-year forecast. Thinks this the last quarter of revenue shrinkage before it gets a major rise in the second half of 2024.
Subdued returns. A leader, critical player in its sector. Stock's lagged due to inventory destocking, higher interest rates, and softer Chinese economy. These issues are largely resolved.
It is the leading company for testing new drugs. It has grown from acquisitions and is now growing at a rate of 5 to7% a year. Buy and hold.
Higher interest rates saw weaker funding in biotech. China had weak demand, though only about 8% of revenues. Still likes it long term for a picks and shovels play.
Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.
Not a major growth company, but will grow steady. ~7% top line growth expected to continue. ~10% share price appreciation expected going forward. Will continue to hold in portfolio.
Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N
In the last year, 17 stock analysts published opinions about TMO-N. 16 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Thermo Fisher Scientific.
Thermo Fisher Scientific was recommended as a Top Pick by on . Read the latest stock experts ratings for Thermo Fisher Scientific.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
17 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.
On 2024-12-06, Thermo Fisher Scientific (TMO-N) stock closed at a price of $528.73.
Touches all aspects of bio-pharma industry. For example, helps run pharmaceutical trials, and helps build and design new drugs. Everything you need, such as electron microscopes, to create new drugs and products.
(Analysts’ price target is $658.90)Weak coming out of Covid, as there was too much inventory in the system. Now primed to see revenue growth reaccelerate. Last time, Trump was favourable to healthcare and biotech. Low multiple relative to its historical average. Yield is 0.3%.